Von Willebrand Disease Pathophysiology

The condition known as von Willebrand disease (vWD) is the result of a reduction in the plasma levels of, or the production of a defective form of, the coagulation factor known as von Willebrand factor (vWF). This is a large glycoprotein made up of many monomers.

Von Willebrand disease- causes, symptoms, diagnosis, treatment, pathology

What is vWF?

The main function of vWF is to bind plasma proteins and, in particular, factor VIII. When unbound, factor VIII rapidly catabolizes. vWF binds to both exposed endothelium and activated platelet receptors, which uncoils and slows down the platelets that are beginning to form a platelet clot, which is the initial step in the coagulation process.

Types of vWD

There are two categories of vWD, which include inherited vWD and acquired vWD. The inherited forms comprise types 1 to 3, with type 2 vWD being subdivided further into 2A, 2B, 2M, and 2N. Each type of inherited vWD varies according to the type and intensity of the defect in vWF.

Since vWF is activated only under conditions of high blood flow and shear stress, organs that have many small vessels, and therefore typically have a slow blood flow, do not have adequate levels of this factor.

Pathophysiology of inherited forms of vWD

Type 1 vWD

Genetically, vWF is altered such that the level of the factor is low. In the dominant severe type 1 vWD, genetic mutations interfere with the intracellular transport of the subunits of this glycoprotein.

Another mechanism is the rapid clearance of the factor from the plasma, leading to a shorter cleavage time of the multimer in circulation by ADAMTS-13. As a result, the distribution pattern of the multimer changes, which leads to a fall in vWF activity.

Type 2 vWD

In type 2 vWD, the plasma vWF level is normal but is structurally and functionally defective. The type of defect is the basis for further subclassification.

Type 2A vWD

Type 2A vWD causes decreased platelet adhesion that is mediated by a deficiency of high molecular weight vWF multimers in circulation. This reduction may be due to either a defect in the assembly of the multimers or an increase in the rate of multimer cleavage. The former is caused by mutations, either homozygous or heterozygous, which prevent multimer formation in the Golgi apparatus.

Type 2B vWD

In type 2 vWD, large multimers are markedly reduced in circulation, while the rate of catabolism is high. This is due to a mutation that allows normal multimerization to occur in the Golgi apparatus but results in the binding of the secreted multimers to the platelets where they are cleaved by ADAMTS-3.

This causes failure of effective platelet adhesion by the abnormally small multimers, with subsequent failure to bind to connective tissue.

Type 2M vWD

In type 2M vWD, vWF-dependent platelet adhesion is reduced, despite a normal level of high molecular weight multimers in plasma. This is due to normal secretion and assembly of multimers, but a mutation-dependent loss of function that prevents the normal binding of vWF to the platelets.

This inability of vWF to bind to platelets exposes less of the multimer to the cleaving enzyme ADAMTS-13, which leads to the persistence of large multimers in distribution that is almost identical to that when they were originally secreted by endothelial cells.

Type 2N vWD

Type 2N vWD is characterized by a very low binding affinity of vWF for factor VIII. Both homozygous and heterozygous mutations responsible for this defect have been recognized. Both alleles may be affected in some cases, but this is rare. The failure to bind factor VIII leads to its rapid catabolism, thereby causing plasma levels of factor VIII to be very low.

Type 3 vWD

Type 3 vWD form is caused by a recessive mutation which results in an almost total absence of vWF, which is why this type is often termed severe vWD.

Acquired vWD

Acquired vWD is due to the rapid clearance of vWF from the plasma after it forms a complex with its antibody. This may be due to its adhesion to tumor cells, the presence of vWF antibodies that disrupt the multimer, or even slow digestion of the protein. Notably, acquired vWD can be seen in patients with aortic stenosis.

References

Further Reading

Last Updated: Apr 25, 2021

Dr. Liji Thomas

Written by

Dr. Liji Thomas

Dr. Liji Thomas is an OB-GYN, who graduated from the Government Medical College, University of Calicut, Kerala, in 2001. Liji practiced as a full-time consultant in obstetrics/gynecology in a private hospital for a few years following her graduation. She has counseled hundreds of patients facing issues from pregnancy-related problems and infertility, and has been in charge of over 2,000 deliveries, striving always to achieve a normal delivery rather than operative.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thomas, Liji. (2021, April 25). Von Willebrand Disease Pathophysiology. News-Medical. Retrieved on October 19, 2021 from https://www.news-medical.net/health/Von-Willebrand-Disease-Pathophysiology.aspx.

  • MLA

    Thomas, Liji. "Von Willebrand Disease Pathophysiology". News-Medical. 19 October 2021. <https://www.news-medical.net/health/Von-Willebrand-Disease-Pathophysiology.aspx>.

  • Chicago

    Thomas, Liji. "Von Willebrand Disease Pathophysiology". News-Medical. https://www.news-medical.net/health/Von-Willebrand-Disease-Pathophysiology.aspx. (accessed October 19, 2021).

  • Harvard

    Thomas, Liji. 2021. Von Willebrand Disease Pathophysiology. News-Medical, viewed 19 October 2021, https://www.news-medical.net/health/Von-Willebrand-Disease-Pathophysiology.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.